Register for our free email digests:
Strategy
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Eastern European Results Roundup: Grindeks, Alkaloid, Olainfarm, Podravka, Sopharma
Several Eastern European generics companies achieved sales growth in 2018. Looking ahead, Grindeks plans to strengthen its presence in Russia and other CIS countries, Alkaloid is set to continue investing in production facilities and technologies, while Olainfarm looks to upgrade its product dossiers.
Accord Agrees Leuprolide Deal as Part of Differentiation Strategy
Zentiva Set To Acquire Romania's Solacium
Zentiva has signed its first acquisition after it was carved out from Sanofi last year to become an independent company, entering into a shared purchase agreement with Siyiara to acquire Romania-based food supplement and OTC medicines producer Solacium.
FDA Approves Pfizer's Trastuzumab Biosimilar
Pfizer’s approval for trastuzumab in the US marks the fourth FDA nod for a biosimilar rival to Genentech’s Herceptin original. However, while two of those biosimilar sponsors continue to be engaged in patent litigation with the originator, Pfizer and Mylan have both struck settlement deals.
Amneal Targets Up to 50 Launches, But Fears Diminishing Returns
Celltrion’s Subcutaneous Infliximab Shows Promise
Data revealed by Korea’s Celltrion demonstrates that the firm’s subcutaneous infliximab is comparable to the intravenous formulation, with a study showing that auto-injection is a viable administrative method.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.